Efficacy and Safety of Potent Oral P2Y12 Inhibitors in Medically Managed ACS Patients: a Meta-analysis.
Sicong MaZhiguo LiPeng YuHaixu SongZaixin JiangYi LiYaling HanPublished in: Cardiovascular drugs and therapy (2020)
Potent oral P2Y12 inhibitors, especially ticagrelor, decrease the risk of ischemic events in MMACS patients as compared with clopidogrel, without significantly increasing major bleeding.